FDA Will Consider OK'ing COVID-19 Vaccine Before End Of Phase 3 Trials

The transcript discusses the potential for the FDA to issue an Emergency Use Authorization (EUA) for COVID-19 vaccines, allowing distribution before phase three trials are complete. It highlights concerns from the American Medical Association about rushing the process and addresses political claims by President Trump that the FDA is delaying vaccine development. The transcript also covers public hesitancy towards vaccines, with a Gallup poll indicating that 35% of Americans would not take a free FDA-approved vaccine. Finally, it provides an update on the status of current vaccine trials in the U.S.

What is the purpose of Emergency Use Authorization (EUA) in the context of COVID-19 vaccines?

• To allow vaccines to be distributed before phase three trials are complete

• To ensure vaccines are only distributed after all trials are complete

• To bypass all clinical trials for faster distribution

• To approve vaccines for international use only

Why did President Trump claim the FDA was slowing down vaccine development?

• To follow scientific guidelines

• To ensure vaccine safety

• To harm his reelection chances

• To increase public trust

What percentage of Americans, according to a Gallup poll, would refuse a free FDA-approved COVID-19 vaccine?

• 50%

• 25%

• 35%

• 10%

What is the main concern of the American Medical Association regarding a rushed COVID-19 vaccine?

• It might be too expensive

• It will only be available in certain regions

• It will not be effective

• It could lead to increased vaccine hesitancy

How many American coronavirus vaccine candidates are currently in phase three trials?

• Five

• Two

• Four

• Three